LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,093
تعداد مقالات10,024
تعداد مشاهده مقاله27,258,914
تعداد دریافت فایل اصل مقاله7,490,471
Zhang, Jingjing, Zhang, Shasha, Xu, Shuo, Zhang, Xiaoyun, Li, Jiasong, Ji, Zhengzheng, Liu, Qingyi, Guo, Zhanjun. (1402). Pulmonary Arterial Hypertension Induced by Immune Checkpoint Inhibitor Combined Therapy in a Patient with Intrahepatic Cholangiocarcinoma: A Case Report. سامانه مدیریت نشریات علمی, 20(2), 240-246. doi: 10.22034/iji.2023.96898.2464
Jingjing Zhang; Shasha Zhang; Shuo Xu; Xiaoyun Zhang; Jiasong Li; Zhengzheng Ji; Qingyi Liu; Zhanjun Guo. "Pulmonary Arterial Hypertension Induced by Immune Checkpoint Inhibitor Combined Therapy in a Patient with Intrahepatic Cholangiocarcinoma: A Case Report". سامانه مدیریت نشریات علمی, 20, 2, 1402, 240-246. doi: 10.22034/iji.2023.96898.2464
Zhang, Jingjing, Zhang, Shasha, Xu, Shuo, Zhang, Xiaoyun, Li, Jiasong, Ji, Zhengzheng, Liu, Qingyi, Guo, Zhanjun. (1402). 'Pulmonary Arterial Hypertension Induced by Immune Checkpoint Inhibitor Combined Therapy in a Patient with Intrahepatic Cholangiocarcinoma: A Case Report', سامانه مدیریت نشریات علمی, 20(2), pp. 240-246. doi: 10.22034/iji.2023.96898.2464
Zhang, Jingjing, Zhang, Shasha, Xu, Shuo, Zhang, Xiaoyun, Li, Jiasong, Ji, Zhengzheng, Liu, Qingyi, Guo, Zhanjun. Pulmonary Arterial Hypertension Induced by Immune Checkpoint Inhibitor Combined Therapy in a Patient with Intrahepatic Cholangiocarcinoma: A Case Report. سامانه مدیریت نشریات علمی, 1402; 20(2): 240-246. doi: 10.22034/iji.2023.96898.2464

Pulmonary Arterial Hypertension Induced by Immune Checkpoint Inhibitor Combined Therapy in a Patient with Intrahepatic Cholangiocarcinoma: A Case Report

Iranian Journal of Immunology
مقاله 10، دوره 20، شماره 2، شهریور 2023، صفحه 240-246    اصل مقاله (1.21 M)
نوع مقاله: Case Report
شناسه دیجیتال (DOI): 10.22034/iji.2023.96898.2464
نویسندگان
Jingjing Zhang1؛ Shasha Zhang1؛ Shuo Xu1؛ Xiaoyun Zhang1؛ Jiasong Li1؛ Zhengzheng Ji1؛ Qingyi Liu2؛ Zhanjun Guo* 1
1Department of Immunology and Rheumatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, P.R. China.
2Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, P.R. China.
چکیده
Immune Checkpoint Inhibitors (ICIs) have dramatically revolutionized the therapeutic approaches by which we treat a series of cancers accompanied by immune-related adverse events (irAEs). Herein, we reported an intrahepatic cholangiocarcinoma male patient with a history of ankylosing spondylitis developing pulmonary arterial hypertension (PAH) under ICI combined therapy with pembrolizumab and lenvatinib. The indirect measurement of cardiac ultrasound showed a pulmonary artery pressure (PAP) of 72mmHg after 21 three-week cycles of ICI combined therapy. The patient partially responded to the treatment of glucocorticoid and mycophenolate mofetil. The PAP decreased to 55mmHg 3 months after the ICI combined therapy was discontinued, but increased to 90mmHg after the ICI combined therapy was rechallenged. We treated him with adalimumab -an antitumor necrosis factor-alpha (ani-TNF-α) antibody- combined with glucocorticoid and immunosuppressants under lenvatinib monotherapy. The patient responded again with PAP decreasing to 67mmHg after 2 two-week cycles of adalimumab. Accordingly, we diagnosed him to have irAE-related PAH. Our findings supported the use of glucocorticoid disease-modifying antirheumatic drugs (DMARDs) as a treatment option in refractory PAH.
کلیدواژه‌ها
Ankylosing Spondylitis؛ Immune-Related Adverse Events؛ Immune Checkpoint Inhibitors؛ Intrahepatic Cholangiocarcinoma؛ Pulmonary Arterial Hypertension
مراجع
  1. Taylor MH, Schmidt EV, Dutcus C, Pinheiro EM, Funahashi Y, Lubiniecki G, et al. The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors. Future oncology (London, England). 2021;17(6):637-48.
  2. Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Human vaccines & immunotherapeutics. 2016;12(11):2777-89.
  3. Makunts T, Burkhart K, Abagyan R, Lee P. Retrospective analysis of clinical trial safety data for pembrolizumab reveals the effect of co-occurring infections on immune-related adverse events. PloS one. 2022;17(2):e0263402.
  4. Glick M, Baxter C, Lopez D, Mufti K, Sawada S, Lahm T. Releasing the brakes: a case report of pulmonary arterial hypertension induced by immune checkpoint inhibitor therapy. Pulmonary circulation. 2020;10(4):2045894020960967.
  5. Wijeratne DT, Lajkosz K, Brogly SB, Lougheed MD, Jiang L, Housin A, et al. Increasing Incidence and Prevalence of World Health Organization Groups 1 to 4 Pulmonary Hypertension: A Population-Based Cohort Study in Ontario, Canada. Circulation Cardiovascular quality and outcomes. 2018;11(2):e003973.
  6. Ni S, Ji T, Dong J, Chen F, Feng H, Zhao H, et al. Immune Cells in Pulmonary Arterial Hypertension. Heart, lung & circulation. 2022.
  7. Ruopp NF, Cockrill BA. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. Jama. 2022;327(14):1379-91.
  8. Chan SY, Loscalzo J. Pathogenic mechanisms of pulmonary arterial hypertension. Journal of molecular and cellular cardiology. 2008;44(1):14-30.
  9. Montani D, Bergot E, Günther S, Savale L, Bergeron A, Bourdin A, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125(17):2128-37.
  10. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clinical pharmacology and therapeutics. 1981;30(2):239-45.
  11. Tobal R, Potjewijd J, van Empel VPM, Ysermans R, Schurgers LJ, Reutelingsperger CP, et al. Vascular Remodeling in Pulmonary Arterial Hypertension: The Potential Involvement of Innate and Adaptive Immunity. Frontiers in medicine. 2021;8:806899.
  12. Tamosiuniene R, Manouvakhova O, Mesange P, Saito T, Qian J, Sanyal M, et al. Dominant Role for Regulatory T Cells in Protecting Females Against Pulmonary Hypertension. Circulation research. 2018;122(12):1689-702.
  13. Austin ED, Rock MT, Mosse CA, Vnencak-Jones CL, Yoder SM, Robbins IM, et al. T lymphocyte subset abnormalities in the blood and lung in pulmonary arterial hypertension. Respiratory medicine. 2010;104(3):454-62.
  14. Bargagli E, Galeazzi M, Bellisai F, Volterrani L, Rottoli P. Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension. Respiration; international review of thoracic diseases. 2008;75(3):346-9.
آمار
تعداد مشاهده مقاله: 985
تعداد دریافت فایل اصل مقاله: 679


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب